Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Icecure Medical ( (ICCM) ) is now available.
On August 13, 2025, IceCure Medical Ltd. released its financial and operational results for the first half of 2025. The company reported a decrease in revenues to $1.25 million from $1.75 million in the same period of 2024, alongside a net loss of $6.95 million. Despite the financial challenges, IceCure continues to focus on expanding its market presence and advancing its cryoablation technology, which may have implications for its stakeholders and industry positioning.
The most recent analyst rating on (ICCM) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is driven primarily by financial challenges, including persistent losses and cash flow issues, despite low leverage. Technical analysis provides mixed signals, and valuation metrics suggest overvaluation due to negative earnings. Positive FDA interactions and regional sales growth are overshadowed by ongoing profitability and revenue challenges.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is a company operating in the medical industry, primarily focusing on the development and commercialization of minimally invasive cryoablation technologies for treating tumors. The company targets the healthcare market with its innovative solutions designed to offer alternatives to traditional surgical procedures.
Average Trading Volume: 1,079,529
Technical Sentiment Signal: Sell
Current Market Cap: $56.33M
See more insights into ICCM stock on TipRanks’ Stock Analysis page.